Other biomarkers for detecting prostate cancer
Authors:
- 5 January 2010
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 105 (2) , 166-169
Abstract
Prostate‐specific antigen (PSA) has been used for detecting prostate cancer since 1994. Although it is the best cancer biomarker available, PSA is not perfect. It lacks both the sensitivity and specificity to accurately detect the presence of prostate cancer. None of the PSA thresholds currently in use consistently identify patients with prostate cancer and exclude patients without cancer. Novel approaches to improve our ability to detect prostate cancer and predict the course of the disease are needed. Additional methods for detecting prostate cancer have been evaluated. Despite the discovery of many new biomarkers, only a few have shown some clinical value. These markers include human kallikrein 2, urokinase‐type plasminogen activator receptor, prostate‐specific membrane antigen, early prostate cancer antigen, PCA3, α‐methylacyl‐CoA racemase and glutathione S‐transferase π hypermethylation. We review the reports on biomarkers for prostate cancer detection, and their possible role in the clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate CancerClinical Chemistry, 2007
- Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or LowerJAMA, 2005
- Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissueThe Prostate, 2004
- THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, 2004
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA eraUrology, 2002
- Free prostate-specific antigen in serum is becoming more complexUrology, 2002
- Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastasesUrology, 1999
- THE EFFECTS OF PROSTATIC MANIPULATION ON PROSTATE-SPECIFIC ANTIGEN LEVELSUrologic Clinics of North America, 1997